Bristol-Myers Squibb

Microsoft

Bristol Myers Squibb Partners with Microsoft to Advance Early Lung Cancer Detection with AI

Undervalued Blue-Chip Stocks to Buy and Hold in 2026: Microsoft and Bristol-Myers Squibb

Syngene Expands Strategic Research Collaboration with Bristol Myers Squibb Through 2035

百时美施贵宝

Bristol-Myers Squibb's 15-Min Chart Shows MACD Death Cross and KDJ Death Cross.

Bristol Myers Squibb Shares Surpass Analyst Target Price, Raising Questions on Valuation and Future Performance.

Catalyst<ul> <li>Recent MACD Golden Cross and Bullish bias signals indicate potential positive momentum for BMY.</li></ul>Risk<ul> <li>Fund flow analysis shows negative net inflow across all order size buckets, indicating investor caution or pessimism toward BMY.</li> <li>Analyst ratings are mixed, with two Neutral ratings, suggesting uncertainty about BMY's near-term prospects.</li> <li>Market expectations for BMY tend to be pessimistic according to recent analyst sentiment data.</li></ul>

Key Factors

Syngene International expanded its strategic research collaboration with Bristol Myers Squibb through 2035 covering drug development from discovery to commercialization.

Recent Updates

BMY News